BIOMAT Database Logo BIOMAT Database Logo

Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ. 2010

Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Laboratory of Tumor Cell Biology, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Previous reports indicate that nuclear factor (NF)-kappaB regulates induction of human immunodeficiency virus type 1 (HIV-1) gene expression in latently infected cells. However, the role of NF-kappaB in cells with active HIV-1 replication is not well understood. In this study, we examined the effect of a new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on HIV-1 replication in a human T cell line and phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PHA-PBMCs). We further explored the mechanism of DHMEQ-mediated inhibition of HIV-1 replication. DHMEQ inhibited HIV-1 replication in HIV-1-infected Molt-4 and PHA-PBMCs. DHMEQ inhibited constitutive NF-kappaB activity in HIV-1-infected PHA-PBMCs and HIV long terminal repeat promoter activity driven by tumor necrosis factor (TNF)-alpha and the trans-activator Tat. The single-round assay using vesicular stomatitis virus-pseudotyped virus in the human T cell line M8166 indicated that DHMEQ treatment resulted in decreased integration of HIV-1 provirus into the host genome and decreased HIV-1 expression. These results indicate that NF-kappaB regulates early events as well as the initial and accelerated expression of HIV-1 in its life cycle. Therefore, we conclude that NF-kappaB is a molecular target for controlling active HIV-1 replication.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003512 Cyclohexanones Cyclohexane ring substituted by one or more ketones in any position.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001549 Benzamides BENZOIC ACID amides.
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
July 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells.
January 2010, Oncology research,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
April 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
November 2007, Leukemia research,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow.
January 2005, Oncology research,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
February 2009, Biochemical and biophysical research communications,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication.
May 2008, PloS one,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ.
January 2009, Current pharmaceutical design,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ.
September 2021, Cells,
Ariko Miyake, and Takaomi Ishida, and Makoto Yamagishi, and Takuma Hara, and Kazuo Umezawa, and Toshiki Watanabe, and Ryouichi Horie
Inhibition of HIV-1 replication in primary human monocytes by the IkappaB-alphaS32/36A repressor of NF-kappaB.
December 2004, Retrovirology,
Copied contents to your clipboard!